Current preclinical models for the advancement of translational bladder cancer research

Molecular Cancer Therapeutics

Volumn 12, Issue 2, 2013, Pages 121-130

  DeGraff, David J ^a   Robinson, Victoria L ^b   Shah, Jay B ^c   Brandt, William D ^d   Sonpavde, Guru ^e   Kang, Yibin ^f   Liebert, Monica ^g   Wu, Xue Ru ^h   Taylor III, John A ⁱ  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f PRINCETON UNIVERSITY   (United States)

^g Society for Clinical and Translational Science   (United States)

^h NEW YORK UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ADENOVIRUS VECTOR; CALCIUM; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; TELOMERASE REVERSE TRANSCRIPTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TROGLITAZONE; UROPLAKIN; UVOMORULIN;

BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL CULTURE; CANCER MODEL; CANCER RESEARCH; CARCINOGENICITY; CARCINOMA IN SITU; CHEMICAL CARCINOGENESIS; CULTURE MEDIUM; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE E6; HUMAN PAPILLOMAVIRUS TYPE E7; METASTASIS; MOLECULAR BIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TIGHT JUNCTION; TRANSITIONAL CELL CARCINOMA; TRANSLATIONAL RESEARCH; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WART VIRUS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; TRANSLATIONAL MEDICAL RESEARCH; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874032693     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0508     Document Type: Review

References (110)

1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-30.
2. Sternberg CN, Collette L. What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer? BJU Int 2006; 98:487-9.
3. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007; 25: 265-70.
4. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34: 1208-12.
5. McCaffrey JA, Herr HW. Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma. Surg Oncol Clin N Am 1997; 6:667-81.
6. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5:713-25.
7. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, et al. Focus on bladder cancer. Cancer Cell 2004; 6:111-6.
8. Degraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urol Oncol. 2011 Sep 14. [Epub ahead of print].
9. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 2012; 148:1132-44.
10. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998; 17:279-84.
11. Kyker KD, Culkin DJ, Hurst RE. A model for 3-dimensional growth of bladder cancers to investigate cell-matrix interactions. Urol Oncol 2003; 21:255-61.
12. Truschel ST, Ruiz WG, Shulman T, Pilewski J, Sun TT, Zeidel ML, et al. Primary uroepithelial cultures. A model system to analyze umbrella cell barrier function. J Biol Chem 1999; 274:15020-9.
13. Reznikoff CA, Johnson MD, Norback DH, Bryan GT. Growth and characterization of normal human urothelium in vitro. In Vitro 1983; 19:326-43.
14. Meisner LF, Wu SQ, Christian BJ, Reznikoff CA. Cytogenetic instability with balanced chromosome changes in an SV40 transformed human uroepithelial cell line. Cancer Res 1988; 48:3215-20.
15. Bookland EA, Swaminathan S, Oyasu R, Gilchrist KW, Lindstrom M, Reznikoff CA. Tumorigenic transformation and neoplastic progression of human uroepithelial cells after exposure in vitro to 4-amino-biphenyl or its metabolites. Cancer Res 1992; 52:1606-14.
16. Reznikoff CA, Belair C, Savelieva E, Zhai Y, Pfeifer K, Yeager T, et al. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev 1994; 8:2227-40.
17. Carmean N, Kosman JW, Leaf EM, Hudson AE, Opheim KE, Bassuk JA. Immortalization of human urothelial cells by human papillomavirus type 16 E6 and E7 genes in a defined serum-free system. Cell Prolif 2007; 40:166-84.
18. Rastogi P, Rickard A, Dorokhov N, Klumpp DJ, McHowat J. Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders. Am J Physiol Renal Physiol 2008; 294:F1129-35.
19. Tamatani T, Hattori K, Nakashiro K, Hayashi Y, Wu S, Klumpp D, et al. Neoplastic conversion of human urothelial cells in vitro by overexpression of H2O2-generating peroxisomal fatty acyl CoA oxidase. Int J Oncol 1999; 15:743-9.
20. Petzoldt JL, Leigh IM, Duffy PG, Sexton C, Masters JR. Immortalisation of human urothelial cells. Urol Res 1995; 23:377-80.
21. Rossi MR, Masters JR, Park S, Todd JH, Garrett SH, Sens MA, et al. The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect 2001; 109:801-8.
22. Wnek SM, Jensen TJ, Severson PL, Futscher BW, Gandolfi AJ. Monomethylarsonous acid produces irreversible events resulting in malignant transformation of a human bladder cell line following 12 weeks of low-level exposure. Toxicol Sci 2010; 116:44-57.
23. Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, Knowles MA. Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene 2006; 25: 5037-45.
24. Ahuja D, Saenz-Robles MT, Pipas JM. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005; 24:7729-45.
25. Wise-Draper TM, Wells SI. Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci 2008; 13:1003-17.
26. Chapman EJ, Kelly G, Knowles MA. Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res 2008; 6: 1154-68.
27. Liebert M, Wedemeyer G, Chang JH, Stein JA, McKeever PE, Carey TE, et al. Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture. J Urol 1990; 144:1288-92.
28. Liebert M, Hubbel A, Chung M, Wedemeyer G, Lomax MI, Hegeman A, et al. Expression of mal is associated with urothelial differentiation in vitro: identification by differential display reverse-transcriptase polymerase chain reaction. Differentiation 1997; 61:177-85.
29. Varley CL, Stahlschmidt J, Smith B, Stower M, Southgate J. Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol 2004; 164:1789-98.
30. Celis A, Rasmussen HH, Celis P, Basse B, Lauridsen JB, Ratz G, et al. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis 1999; 20: 355-61.
31. Hayflick L. The cell biology of aging. J Invest Dermatol 1979; 73:8-14.
32. Rigby CC, Franks LM. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. Br J Cancer 1970; 24:746-54.
33. Benham F, Cottell DC, Franks LM, Wilson PD. Alkaline phosphatase activity in human bladder tumor cell lines. J Histochem Cytochem 1977; 25:266-74.
34. Liebert M, Wedemeyer GA, Stein JA, Washington RW Jr, Flint A, Ren LQ, et al. Identification by monoclonal antibodies of an antigen shed by human bladder cancer cells. Cancer Res 1989; 49:6720-6.
35. Liebert M, Gebhardt D, Wood C, Chen IL, Ellard J, Amancio D, et al. Urothelial differentiation and bladder cancer. Adv Exp Med Biol 1999; 462:437-48.
36. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010; 38:D652-7.
37. O'Toole CM, Povey S, Hepburn P, Franks LM. Identityof some human bladder cancer cell lines. Nature 1983; 301:429-30.
38. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 2001; 98:8012-7.
39. Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, et al. Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer 2010; 127:1-8.
40. Dirks WG, MacLeod RA, Nakamura Y, Kohara A, Reid Y, Milch H, et al. Cell line cross-contamination initiative: an interactive reference database of STR profiles covering common cancer cell lines. Int J Cancer 2010; 126:303-4.
41. Chan ES, Patel AR, SmithAK, Klein JB, Thomas AA, Heston WD, et al. Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. J Urol 2009; 182:2926-31.
42. Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, Agarwal PK, et al. Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU Int 2010; 106:1799-804.
43. Hadaschik BA, Black PC, Sea JC, Metwalli AR, Fazli L, Dinney CP, et al. A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int 2007; 100:1377-84.
44. Jurczok A, Fornara P, Soling A. Bioluminescence imaging to monitor bladder cancer cell adhesion in vivo: a new approach to optimize a syngeneic, orthotopic, murine bladder cancer model. BJU Int 2008; 101:120-4.
45. Deroose CM, De A, Loening AM, Chow PL, Ray P, Chatziioannou AF, et al. Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and biolu-minescence imaging. J Nucl Med 2007; 48:295-303.
46. Chan E, Patel A, Heston W, Larchian W. Mouse orthotopic models for bladder cancer research. BJU Int 2009; 104:1286-91.
47. Sengelov L, Kamby C, von der Maase H. Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol 1996; 155:111-4.
48. Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res 2004; 64:7813-21.
49. Wu CL, Shieh GS, Chang CC, Yo YT, Su CH, Chang MY, et al. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models. Clin Cancer Res 2008; 14:1228-38.
50. Zhou JH, Rosser CJ, Tanaka M, Yang M, Baranov E, Hoffman RM, et al. Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Ther 2002; 9:681-6.
51. Chaffer CL, Dopheide B, McCulloch DR, Lee AB, Moseley JM, Thompson EW, et al. Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder. Clin Exp Metastasis 2005; 22: 115-25.
52. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 2007; 75:831-42.
53. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006; 66:11271-8.
54. Kovnat A, Buick RN, Choo B, De Harven E, Kopelyan I, Trent JM, et al. Malignant properties of sublines selected from a human bladder cancer cell line that contains an activated c-Ha-ras oncogene. Cancer Res 1988; 48:4993-5000.
55. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002; 62:6418-23.
56. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005; 11:4044-55.
57. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003; 33:90-6.
58. Wu XR, Manabe M, Yu J, Sun TT. Large scale purification and immunolocalization of bovine uroplakins I, II, and III. Molecular markers of urothelial differentiation. J Biol Chem 1990; 265: 19170-9.
59. Wu XR, Lin JH, Walz T, Haner M, Yu J, Aebi U, et al. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem 1994; 269:13716-24.
60. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999; 59:3512-7.
61. Mo L, Zheng X, Huang HY, ShapiroE, Lepor H, Cordon-CardoC, et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 2007; 117:314-25.
62. Gao J, Huang HY, Pak J, Cheng J, Zhang ZT, Shapiro E, et al. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene 2004; 23:687-96.
63. Cheng J, Huang H, Zhang ZT, Shapiro E, Pellicer A, Sun TT, et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 2002; 62:4157-63.
64. Mo L, Cheng J, Lee EY, Sun TT, Wu XR. Gene deletion in urothelium by specific expression of Cre recombinase. Am J Physiol Renal Physiol 2005; 289:F562-8.
65. He F, Mo L, Zheng XY, Hu C, Lepor H, Lee EY, et al. Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res 2009; 69:9413-21.
66. Gao H, Ouyang X, Banach-Petrosky W, Borowsky AD, Lin Y, Kim M, et al. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 2004; 101: 17204-9.
67. Cheng J, Huang H, Pak J, Shapiro E, Sun TT, Cordon-Cardo C, et al. Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Res 2003; 63:179-85.
68. Wu XR. Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev 2009; 28:281-90.
69. Khandelwal P, Abraham SN, Apodaca G. Cell biology and physiology of the uroepithelium. Am J Physiol Renal Physiol 2009; 297:F1477-501.
70. Zhou H, Liu Y, He F, Mo L, Sun TT, Wu XR. Temporally and spatially controllable gene expression and knockout in mouse urothelium. Am J Physiol Renal Physiol 2010; 299:F387-95.
71. Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer 1972; 8:587-94.
72. Ohtani M, Kakizoe T, Nishio Y, Sato S, Sugimura T, Fukushima S, et al. Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 1986; 46:2001-4.
73. Ohtani M, Kakizoe T, Sato S, Sugimura T, Fukushima S. Strain differences in mice with invasive bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. J Cancer Res Clin Oncol 1986; 112:107-10.
74. Taylor JA III, Kuchel GA, Hegde P, Voznesensky OS, Claffey K, Tsimikas J, et al. Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice. BMC Cancer 2007; 7:135.
75. Grubbs CJ, Moon RC, Squire RA, Farrow GM, Stinson SF, Goodman DG, et al. 13-cis-Retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. Science 1977; 198:743-4.
76. Thompson HJ, Becci PJ, Grubbs CJ, Shealy YF, Stanek EJ, Brown CC, et al. Inhibition of urinary bladder cancer by N-(ethyl)-all-trans-retinamide and N-(2-hydroxyethyl)-all-trans-retinamide in rats and mice. Cancer Res 1981; 41:933-6.
77. Taylor JA, Choudhary S, Hegde P, Voznesensky OS, Cruz VFdl, Pruitt JR, et al. The use of oral inhibitors of macrophage migration inhibitory factor in a mouse model of bladder cancer significantly reduce tumor burden [abstract]. In: Proceedings of the AACR Annual Meeting; 2010; Washington, DC. Philadelphia, PA: AACR; 2010. p. 373.
78. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23:675-80.
79. Khandelwal P, Ruiz WG, Balestreire-Hawryluk E, Weisz OA, Gold-enring JR, Apodaca G. Rab11a-dependent exocytosis of discoidal/ fusiform vesicles in bladder umbrella cells. Proc Natl Acad Sci U S A 2008; 105:15773-8.
80. Ramesh N, Memarzadeh B, Ge Y, Frey D, VanRoey M, Rojas V, et al. Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. Mol Ther 2004; 10:697-705.
81. Staack A, Donjacour AA, Brody J, Cunha GR, Carroll P. Mouse urogenital development: a practical approach. Differentiation 2003; 71:402-13.
82. DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, et al. Loss of th urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS ONE 2012; 7:e36669.
83. Hicks RM. Discussion of morphological markers of early neoplastic change in the urinary bladder. Cancer Res 1977; 37:2822-3.
84. Uchida K, Samma S, Momose H, Kashihara N, Rademaker A, Oyasu R. Stimulation of urinary bladder tumorigenesis by carcinogen-exposed stroma. J Urol 1990; 143:618-21.
85. Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson EG, et al. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res 2008; 68:4709-18.
86. Li X, Wang Y, Sharif-Afshar AR, Uwamariya C, Yi A, Ishii K, et al. Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling. Differentiation 2009; 77: 95-102.
87. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009; 106:14016-21.
88. He X, Marchionni L, Hansel DE, Yu W, Sood A, Yang J, et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 2009; 27:1487-95.
89. Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 2002; 62:6973-80.
90. Masters JR, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, et al. Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res 1986; 46:3630-6.
91. Markl ID, Jones PA. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 1998; 58:5348-53.
92. Liu J, Babaian DC, Liebert M, Steck PA, Kagan J. Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. Mol Carcinog 2000; 29:143-50.
93. Fogh J. Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl Cancer Inst Monogr 1978; 49:5-9.
94. da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos Junior GA, Sakamoto-Hojo ET, Salvadori DM. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med (Maywood) 2010; 235:814-24.
95. Baumgart E, Cohen MS, Silva Neto B, Jacobs MA, Wotkowicz C, Rieger-Christ KM, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007; 13:1685-94.
96. Rieger KM, Little AF, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT, et al. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer 1995; 72:683-90.
97. Matsui Y, Watanabe J, Ding S, Nishizawa K, Kajita Y, Ichioka K, et al. Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wildtype urothelial cancer cells through p38 activation. BJU Int 2010; 105:558-64.
98. Gallagher EM, O'Shea DM, Fitzpatrick P, Harrison M, Gilmartin B, Watson JA, et al. Recurrence of urothelial carcinoma of the bladder: a role for insulin-like growth factor-II loss of imprinting and cytoplasmic E-cadherin immunolocalization. Clin Cancer Res 2008; 14:6829-38.
99. Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982; 297:474-8.
100. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 1973; 11: 765-73.
101. Pagliaro LC, Keyhani A, Liu B, Perrotte P, Wilson D, Dinney CP. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol 2003; 21: 456-62.
102. O'Toole C, Price ZH, Ohnuki Y, Unsgaard B. Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma. Br J Cancer 1978; 38:64-76.
103. Quentmeier H, Zaborski M, Drexler HG. The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines. Leuk Res 1997; 21:343-50.
104. Zhang G, Chen F, Cao Y, See WA. Bacillus Calmette-Guerin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway. Urol Oncol 2007; 25: 221-7.
105. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008; 14:1478-86.
106. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 2007; 6:277-85.
107. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995; 154:1532-8.
108. Nayak SK, O'Toole C, Price ZH. A cell line from an anaplastic transitional cell carcinoma of human urinary bladder. Br J Cancer 1977; 35:142-51.
109. O'Toole C, Nayak S, Price Z, Gilbert WH, Waisman J. A cell line (SCABER) derived from squamous cell carcinoma of the human urinary bladder. Int J Cancer 1976; 17:707-14.
110. Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, Zou C, et al. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol 2006; 175:1133-7.